Depew W, Boyer T, Omata M, Redeker A, Reynolds T
Gastroenterology. 1980 Mar;78(3):524-9.
Twenty-eight patients entered a double-blind controlled trial to evaluate the efficacy of prednisolone treatment in severe acute alcoholic hepatitis accompanied by encephalopathy. Fifty-three percent (8 of 15) given prednisolone and 54% (7 of 13) given placebo died during the study. The mean duration of hospitalization was 66 days for the prednisolone-treated group and 56 days for those treated with placebo. Prednisolone treatment produced no important beneficial effect on any of the hepatic biochemical tests. The outcome in any particular case was directly related to the development of specific lethal complications (renal failure, injection, and gastrointestinal bleeding) rather than to the treatment employed. We were unable to show any beneficial effect of prednisolone treatment on morbidity or mortality in patients with severe acute alcoholic hepatitis and encephalopathy.
28名患者进入一项双盲对照试验，以评估泼尼松龙治疗伴有脑病的严重急性酒精性肝炎的疗效。在研究期间，接受泼尼松龙治疗的患者中有53%（15例中的8例）死亡，接受安慰剂治疗的患者中有54%（13例中的7例）死亡。泼尼松龙治疗组的平均住院时间为66天，安慰剂治疗组为56天。泼尼松龙治疗对任何肝脏生化检查均未产生重要的有益效果。任何特定病例的结果都与特定致命并发症（肾衰竭、感染和胃肠道出血）的发生直接相关，而不是与所采用的治疗方法相关。我们未能证明泼尼松龙治疗对严重急性酒精性肝炎和脑病患者的发病率或死亡率有任何有益影响。
